Trial · NCT02489227
Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis
NCT02489227, Phase 3, Completed, Coherus Oncology, Inc.; results first posted 2019-10-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis. Trials, record NCT02489227. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02489227
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis
- NCT number
- NCT02489227
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 545 participants, actual
- Lead sponsor
- Coherus Oncology, Inc.
- Conditions
- Plaque Psoriasis
- Interventions
- CHS-1420, Adalimumab
- First posted
- 2015-07-02
- Last updated
- 2020-04-08
- Results first posted
- 2019-10-18
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Difference Between the Percentage of Subjects in Each Treatment Group Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI-75) at Week 12 | 12 weeks | The efficacy success criterion was the equivalence between CHS-1420 and Humira at Week 12. Equivalence was based upon 2-sided 95% confidence interval (CI) for the difference between the proportions of subjects in the CHS-1420 and Humira groups achieving PASI-75 at Week 12. If the 95% CI lay entirely within the interval (-15%, 15%), equivalence was established. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Difference Between the Percentage of Subjects in Each Treatment Group Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI-75) at Week 12 | 12 weeks | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Difference Between the Percentage of Subjects in Each Treatment Group Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI-75) at Week 12 | Humira (Adalimumab) | 203 | Participants | ||
| Difference Between the Percentage of Subjects in Each Treatment Group Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI-75) at Week 12 | CHS-1420 | 211 | Participants |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | CHS-1420 | 274 | |
| Overall Study | STARTED | Humira (Adalimumab) Reassigned to CHS-1420 | 135 | |
| Overall Study | STARTED | Humira (Adalimumab) | 136 | |
| Overall Study | COMPLETED | CHS-1420 | 220 | |
| Overall Study | COMPLETED | Humira (Adalimumab) Reassigned to CHS-1420 | 101 | |
| Overall Study | COMPLETED | Humira (Adalimumab) | 117 | |
| Overall Study | NOT COMPLETED | CHS-1420 | 54 | |
| Overall Study | NOT COMPLETED | Humira (Adalimumab) Reassigned to CHS-1420 | 34 | |
| Overall Study | NOT COMPLETED | Humira (Adalimumab) | 19 |
Source ClinicalTrials.gov
Adverse events162
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nasopharyngitis | Infections and infestations | Treatment Period 1: CHS-1420 | 24 | 274 | 24 |
| other | Nasopharyngitis | Infections and infestations | Treatment Period 1: Humira (Adalimumab) | 24 | 271 | 24 |
| other | Nasopharyngitis | Infections and infestations | Treatment Period 2: CHS-1420/CHS-1420 | 0 | 255 | 0 |
| other | Nasopharyngitis | Infections and infestations | Treatment Period 2: Humira/CHS-1420 | 0 | 126 | 0 |
| other | Nasopharyngitis | Infections and infestations | Teatment Period 2: Humira/Humira | 0 | 130 | 0 |
| other | Nasopharyngitis | Infections and infestations | Treatment Period 3: Open Label CHS-1420 Extension | 0 | 474 | 0 |
| other | Upper respiratory tract infection | Infections and infestations | Treatment Period 1: CHS-1420 | 17 | 274 | 17 |
| other | Upper respiratory tract infection | Infections and infestations | Treatment Period 1: Humira (Adalimumab) | 14 | 271 | 14 |
| other | Upper respiratory tract infection | Infections and infestations | Treatment Period 2: CHS-1420/CHS-1420 | 0 | 255 | 0 |
| other | Upper respiratory tract infection | Infections and infestations | Treatment Period 2: Humira/CHS-1420 | 0 | 126 | 0 |
1 to 10 of 162Source ClinicalTrials.gov
See all 162 adverse eventsAdverse event totals18
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment Period 1: CHS-1420 | 0 | 274 |
| Total, all-cause mortality | Treatment Period 1: Humira (Adalimumab) | 0 | 271 |
| Total, all-cause mortality | Treatment Period 2: CHS-1420/CHS-1420 | 0 | 255 |
| Total, all-cause mortality | Treatment Period 2: Humira/CHS-1420 | 0 | 126 |
| Total, all-cause mortality | Teatment Period 2: Humira/Humira | 0 | 130 |
| Total, all-cause mortality | Treatment Period 3: Open Label CHS-1420 Extension | 1 | 474 |
| Total, other adverse events | Treatment Period 1: CHS-1420 | 41 | 274 |
| Total, other adverse events | Treatment Period 1: Humira (Adalimumab) | 38 | 271 |
| Total, other adverse events | Treatment Period 2: CHS-1420/CHS-1420 | 0 | 255 |
| Total, other adverse events | Treatment Period 2: Humira/CHS-1420 | 0 | 126 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Humira (Adalimumab) vs CHS-1420: Difference Between the Percentage of Subjects in Each Treatment Group Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI-75) at Week 12 |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02489227
GET https://conductscience.org/api/trials/v1/NCT02489227/events?page=2